Nivolumab-associated Nasal Polyposis and Eosinophilic Asthma Responsive to Benralizumab, An Anti-IL5R Biologic. J Immunother 2022 Oct 01;45(8):370-373
Date
08/02/2022Pubmed ID
35913799DOI
10.1097/CJI.0000000000000430Scopus ID
2-s2.0-85137746066 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
We present a case report of nivolumab-aggravated treatment-resistant chronic rhinosinusitis with nasal polyposis with asthma, suggestive of aspirin-exacerbated respiratory disease, normalized with the IL-5R antagonist benralizumab. For patients experiencing symptomatic complications of immunotherapy-associated eosinophilia, this case suggests anti-IL-5(R) biologics may durably resolve nasal polyposis and asthma symptoms, permitting continuity of checkpoint inhibitor therapy and sparing of systemic corticosteroids. Postulated mechanisms of checkpoint inhibition favoring eosinophilia and polyposis, and the uncertain effect of eosinophil reduction upon malignancy progression, are reviewed.
Author List
Rembalski S, Steinberg JAAuthor
Joshua A. Steinberg MD Associate Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibodies, Monoclonal, HumanizedAsthma
Biological Products
Eosinophilia
Humans
Nasal Polyps
Sinusitis
